L-苯丙酰胺，D-精氨酰-2,6-二甲基-L-酪氨酰-L-赖氨酰-

L-苯丙酰胺，D-精氨酰-2,6-二甲基-L-酪氨酰-L-赖氨酰-（CAS 736992-21-5）的公开数据库记录，列此仅供独立核对。

这个物质在各数据库里的编号

数据库记载的用途

• Under accelerated approval in the US, elamipretide is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
• Elamipretide exposure increases proportionally over a dose range of 2 to 80 mg following daily subcutaneous injections with minimal accumulation. Maximum elamipretide concentrations were reached between 0.5 to 1 hour after subcutaneous administration. The absolute bioavailability following subcutaneous administration is approximately 92%. Elamipretide exposure is comparable after subcutaneous injection to the thigh or to the abdomen.
• Elamipretide and its metabolites M1 and M2 are excreted in the urine. At 48 hours post-dose, approximately 100% of the elamipretide dose was recovered in the urine as either elamipretide, M1, or M2 in patients with normal renal function.
• Elamipretide is distributed throughout total body water with an approximate volume of distribution of 0.5 L/kg.
• Protein binding is approximately 39%.
• Elamipretide is metabolized via sequential C-terminal degradation to the M1 tripeptide and M2 dipeptide metabolites, which do not have pharmacological activity. The metabolic pathways have not been fully characterized.

它在各数据库里的别名

Elamipretide; 736992-21-5; bendavia; Ocuvia; MTP-131; MTP 131; SS-31; Szeto-schiller peptide; Elamipretida; MTP131; Nh2-d-arg-dmt-lys-phe-nh2; RX 31; SS 31; 87GWG91S09; RX-31; elamipretidum

计算机算出的分子描述符

数据库摘要

L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl- · CAS 736992-21-5 · C32H49N9O5. UNII 87GWG91S09.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。